eligard™ 22,5 mg
1's (1 pre-filled syringe a + 1 pre-filled syringe b) -
eligard™ 45mg
1's (1 pre-filled syringe a + 1 pre-filled syringe b) -
eligard™ 7,5mg
1's (1 pre-filled syringe a + 1 pre-filled syringe b) -
eligard 7.5 mg powder for solution for injection powder and solvent for solution for injection
astellas pharma, netherlands - leuprorelin - powder and solvent for solution for injection - 7.5 mg
eligard 22.5 mg powder for solution for injection powder and solvent for solution for injection
astellas pharma, netherlands - leuprorelin - powder and solvent for solution for injection - 22.5 mg
eligard 45 mg powder for solution for injection powder and solvent for solution for injection
astellas pharma, netherlands - leuprorelin - powder and solvent for solution for injection - 45 mg
camcevi
accord healthcare s.l.u. - leuprorelin mesilate - prostatic neoplasms - endocrine therapy - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
leuprorelin endomedica 11,25 fertigspritze mit implantat